Rhegen Biotech focuses on major infectious diseases, oncology, autoimmune disorders, and other therapeutic areas, committed to developing mRNA-based drugs and therapies. Throughout our R&D process, we have progressively accumulated and solidified foundational mRNA technologies and multiple core patents, establishing a comprehensive technological capability platform encompassing all key elements of the mRNA field.

Leveraging clinical and druggability insights, Rhegen Biotech efficiently design and develop highly accessible mRNA vaccines and therapeutics from the very beginning. We are dedicated to becoming an innovative biopharmaceutical enterprise with domestic leadership, international competitiveness, and core technological advantages.